Evidence map›Paper›PMID 32216452›Full record

ArticleActa radiologica (Stockholm, Sweden : 1987)2020

Quantification of contrast-uptake as imaging biomarker for disease progression of renal cell carcinoma after tumor ablation.

Bruno R Tegel, Steffen Huber, Lynn J Savic, MingDe Lin, Bernhard Gebauer, Jeffrey Pollak, Julius Chapiro

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Acta radiologica (Stockholm, Sweden : 1987), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Bruno R TegelYale School of Medicine, Department of Radiology and Biomedical Imaging, New Haven, CT, USA.ORCID https://orcid.org/0000-0003-0440-7783
Steffen HuberYale School of Medicine, Department of Radiology and Biomedical Imaging, New Haven, CT, USA.
Lynn J SavicYale School of Medicine, Department of Radiology and Biomedical Imaging, New Haven, CT, USA.ORCID https://orcid.org/0000-0003-2115-6728
MingDe LinU/S Imaging and Interventions, Philips Research North America, Cambridge, MA, USA.
Bernhard GebauerCharité Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt Universität Berlin and Berlin Institute of Health, Institute of Radiology, Berlin, Germany.
Jeffrey PollakYale School of Medicine, Department of Radiology and Biomedical Imaging, New Haven, CT, USA.
Julius ChapiroYale School of Medicine, Department of Radiology and Biomedical Imaging, New Haven, CT, USA.

Funding

Yale Clinical and Translational Science Award (U Component)UL1TR001863 · NCATS · YALE UNIVERSITY · PI John H. Krystal, LUCILA OHNO-MACHADO · 2016 to 2026
$102.9M
Quantitative Multimodal Imaging Biomarkers for Combined Locoregional and Immunotherapy of Liver CancerR01CA206180 · NCI · YALE UNIVERSITY · PI CHAPIRO, JULIUS, DUNCAN, JAMES S · 2016 to 2025
$6.1M
NCATS NIH HHS UL1 TR001863NCI NIH HHS R01 CA206180
6 · The paper itself

Abstract

backgroundThe prognosis of patients with renal cell carcinoma (RCC) depends greatly on the presence of extra-renal metastases. PURPOSE: To investigate the value of total tumor volume (TTV) and enhancing tumor volume (ETV) as three-dimensional (3D) quantitative imaging biomarkers for disease aggressiveness in patients with RCC. MATERIAL AND

methodsRetrospective, HIPAA-compliant, IRB-approved study including 37 patients with RCC treated with image-guided thermal ablation during 2007-2015. TNM stage, RENAL Nephrometry Score, largest tumor diameter, TTV, and ETV were assessed on cross-sectional imaging at baseline and correlated with outcome measurements. The primary outcome was time-to-occurrence of extra-renal metastases and the secondary outcome was progression-free survival (PFS). Correlation was assessed using a Cox regression model and differences in outcomes were shown by Kaplan-Meier plots with significance and odds ratios (OR) calculated by Log-rank test/generalized Wilcoxon and continuity-corrected Woolf logit method.

resultsPatients with a TTV or ETV > 5 cm

conclusionETV, as surrogate of lesion vascularity, is a sensitive imaging biomarker for occurrence of extra-renal metastatic disease and PFS in patients with RCC.

Indexed as

Radiography, InterventionalUltrasonography, InterventionalAblation TechniquesAdultAgedAged, 80 and overBiomarkers, TumorCarcinoma, Renal CellContrast MediaDisease ProgressionFemaleHumansImaging, Three-DimensionalKidney NeoplasmsMaleMiddle AgedBiomarkers, TumorContrast MediabiomarkersmetastasesprognosisRenal cell carcinomatumor volume

Identifiers

PMID32216452
PMCPMC7529766

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.